Table 4.

LG100268, alone and in combination with C/P, is effective for the treatment of established lung tumors in A/J mice

(mg/kg diet)ControlLG100268100C/PLG268 + C/P
Tumor number, size, and burden
 Number of slides52244224
 Average number of tumors (% control)3.4 ± 0.25 (100%)2.2 ± 0.28a (64%)2.1 ± 0.17a (63%)1.3 ± 0.26a,b (39%)
 Average tumor size, mm3 (% control)0.58 ± 0.09 (100%)0.24 ± 0.03a (41%)0.19 ± 0.02a (33%)0.11 ± 0.02a,b (18%)
 Average tumor burden, mm3 (% control)1.99 ± 0.34 (100%)0.52 ± 0.12a (26%)0.41 ± 0.06a (21%)0.14 ± 0.05a,b (7%)
Tumor histopathology
 Number of tumors177529032
 Total number of low-grade tumors (% total)2 (1%)1 (2%)5 (6%)3a (9%)
 Total number of medium-grade tumors (% total)50 (28%)24a (46%)46a (51%)18a (56%)
 Total number of high-grade tumors (% total)125 (71%)27a (52%)39c (43%)11a (35%)

NOTE: Female A/J mice were injected i.p. with a single dose of vinyl carbamate (0.32 mg/mouse). Twelve weeks after the carcinogen treatment, mice were fed for 12 weeks with either control diet or 100 mg LG268/kg diet. Six weekly i.p. injections of carboplatin (C—50 mg/kg i.p.) and paclitaxel (P—15 mg/kg i.p.) were started 1 week after the LG268 treatment diet was started. Values shown are mean ± SEM.

  • aP < 0.05 vs. control.

  • bP < 0.05 vs. LG268 or C/P alone.

  • cP < 0.001 vs. control.